Atrial fibrillation

Area of Science:

• Cardiology
• Geriatrics
• Pharmacology

Background:

• The incidence and prevalence of atrial fibrillation (AF) are rising due to population aging and increased age-adjusted incidence.
• Management decisions for AF, including rate or rhythm control, are influenced by patient age, comorbidities, symptoms, and hemodynamic status.

Purpose of the Study:

• To review current strategies for managing atrial fibrillation, focusing on rate versus rhythm control and antithrombotic prophylaxis.
• To provide guidance on selecting appropriate medications for rate control and optimizing stroke risk assessment and prevention in AF patients.

Main Methods:

• Literature review of studies on atrial fibrillation management, rate control, rhythm control, and antithrombotic therapies.
• Analysis of current guidelines and evidence regarding drug efficacy and safety for AF treatment.
• Evaluation of stroke risk stratification tools, specifically the CHADS2 score, for guiding antithrombotic selection.

Main Results:

• Beta-blockers, verapamil, and diltiazem are preferred for rate control over digoxin, especially during exercise.
• Anti-arrhythmic drugs have limited long-term success (40%-60% at 1 year) and significant side effects.
• The CHADS2 score effectively estimates ischemic stroke risk, guiding antithrombotic choices.
• Warfarin is recommended for patients with valvular AF or CHADS2 score ≥2, while aspirin may be suitable for lower-risk patients.
• Stroke rates are comparable across different AF types (paroxysmal, persistent, permanent) and likely atrial flutter.

Conclusions:

• Either rate or rhythm control is acceptable for AF management, with choices individualized.
• Antithrombotic prophylaxis selection is independent of rate/rhythm control strategy and primarily based on stroke risk assessed by the CHADS2 score.
• Warfarin is indicated for high-risk patients, while aspirin is an option for those with lower stroke risk or contraindications to warfarin.